Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer

Ahmet Murat Aydin, Solomon L. Woldu, Ryan C. Hutchinson, Martin Boegemann, Aditya Bagrodia, Yair Lotan, Vitaly Margulis, Laura Maria Krabbe

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic therapies. The current standard of care includes multiagent platinum-based chemotherapy; however a majority of patients do not respond to treatment and most eventually succumb to disease. Recently, renewed interest in immunotherapy in the form of immune-checkpoint inhibition has gained widespread attention for a number of malignancies. Atezolizumab, an anti-PDL1 antibody, has been shown to be effective in a subset of patients previously treated with or unfit for platinum-based chemotherapy, and has shown durable responses with a good tolerability profile. We review the mechanism of action and clinical evidence of atezolizumab for metastatic urothelial bladder cancer, and discuss this drug within the context of ongoing developments in this dynamic field of immunooncology.

Original languageEnglish (US)
Pages (from-to)1487-1502
Number of pages16
JournalOncoTargets and Therapy
Volume10
DOIs
StatePublished - Mar 9 2017

Fingerprint

Platinum
Urinary Bladder Neoplasms
Drug Therapy
Standard of Care
Immunotherapy
Anti-Idiotypic Antibodies
Neoplasms
Urinary Bladder
Carcinoma
Therapeutics
Pharmaceutical Preparations
MPDL3280A

Keywords

  • Atezolizumab
  • Bladder cancer
  • Immunotherapy
  • Metastatic
  • MPDL3280A
  • PDL1

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. / Aydin, Ahmet Murat; Woldu, Solomon L.; Hutchinson, Ryan C.; Boegemann, Martin; Bagrodia, Aditya; Lotan, Yair; Margulis, Vitaly; Krabbe, Laura Maria.

In: OncoTargets and Therapy, Vol. 10, 09.03.2017, p. 1487-1502.

Research output: Contribution to journalReview article

@article{68c2f13ee8074215af1a21493b41614f,
title = "Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer",
abstract = "Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic therapies. The current standard of care includes multiagent platinum-based chemotherapy; however a majority of patients do not respond to treatment and most eventually succumb to disease. Recently, renewed interest in immunotherapy in the form of immune-checkpoint inhibition has gained widespread attention for a number of malignancies. Atezolizumab, an anti-PDL1 antibody, has been shown to be effective in a subset of patients previously treated with or unfit for platinum-based chemotherapy, and has shown durable responses with a good tolerability profile. We review the mechanism of action and clinical evidence of atezolizumab for metastatic urothelial bladder cancer, and discuss this drug within the context of ongoing developments in this dynamic field of immunooncology.",
keywords = "Atezolizumab, Bladder cancer, Immunotherapy, Metastatic, MPDL3280A, PDL1",
author = "Aydin, {Ahmet Murat} and Woldu, {Solomon L.} and Hutchinson, {Ryan C.} and Martin Boegemann and Aditya Bagrodia and Yair Lotan and Vitaly Margulis and Krabbe, {Laura Maria}",
year = "2017",
month = "3",
day = "9",
doi = "10.2147/OTT.S109453",
language = "English (US)",
volume = "10",
pages = "1487--1502",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer

AU - Aydin, Ahmet Murat

AU - Woldu, Solomon L.

AU - Hutchinson, Ryan C.

AU - Boegemann, Martin

AU - Bagrodia, Aditya

AU - Lotan, Yair

AU - Margulis, Vitaly

AU - Krabbe, Laura Maria

PY - 2017/3/9

Y1 - 2017/3/9

N2 - Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic therapies. The current standard of care includes multiagent platinum-based chemotherapy; however a majority of patients do not respond to treatment and most eventually succumb to disease. Recently, renewed interest in immunotherapy in the form of immune-checkpoint inhibition has gained widespread attention for a number of malignancies. Atezolizumab, an anti-PDL1 antibody, has been shown to be effective in a subset of patients previously treated with or unfit for platinum-based chemotherapy, and has shown durable responses with a good tolerability profile. We review the mechanism of action and clinical evidence of atezolizumab for metastatic urothelial bladder cancer, and discuss this drug within the context of ongoing developments in this dynamic field of immunooncology.

AB - Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic therapies. The current standard of care includes multiagent platinum-based chemotherapy; however a majority of patients do not respond to treatment and most eventually succumb to disease. Recently, renewed interest in immunotherapy in the form of immune-checkpoint inhibition has gained widespread attention for a number of malignancies. Atezolizumab, an anti-PDL1 antibody, has been shown to be effective in a subset of patients previously treated with or unfit for platinum-based chemotherapy, and has shown durable responses with a good tolerability profile. We review the mechanism of action and clinical evidence of atezolizumab for metastatic urothelial bladder cancer, and discuss this drug within the context of ongoing developments in this dynamic field of immunooncology.

KW - Atezolizumab

KW - Bladder cancer

KW - Immunotherapy

KW - Metastatic

KW - MPDL3280A

KW - PDL1

UR - http://www.scopus.com/inward/record.url?scp=85015176945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015176945&partnerID=8YFLogxK

U2 - 10.2147/OTT.S109453

DO - 10.2147/OTT.S109453

M3 - Review article

C2 - 28331342

AN - SCOPUS:85015176945

VL - 10

SP - 1487

EP - 1502

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -